Pharmaceuticals

Pertussis Vaccine Market 2025–2029: Strategic Opportunities and Growth Insights

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pertussis vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Pertussis Vaccine Market Now And By 2029?

The market size for asparaginase for injection has consistently expanded in recent years. This market is set to increase from $2.07 billion in 2024 to $2.16 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.3%. Key factors contributing to its historical growth include escalating healthcare expenditure, an intensified focus on pediatric cancer treatment, substantial unmet medical needs, the provision of reimbursements, a rise in cancer prevalence, enhancements in healthcare infrastructure, and increased awareness of rare diseases.

The market size for asparaginase for injection is anticipated to demonstrate robust expansion over the next few years, projected to reach $2.65 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.3%. This growth during the forecast period is primarily driven by the increasing demand for targeted cancer therapies, augmented healthcare investments, a proliferation of pharmaceutical partnerships, an expanding geriatric demographic, a rising volume of clinical trials, and the imperative for precision medicine. Noteworthy trends identified for the forecast period include the adoption of personalized medicine, combination therapies utilizing chemotherapy, continuous advancements within biotechnology, innovations in drug delivery systems, a discernible shift towards intravenous formulations, a heightened focus on patient-centered care, and the development of alternative cancer treatment strategies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23319&type=smp

Which Long-Term Drivers Are Expected To Sustain The Pertussis Vaccine Market?

The increasing occurrence of leukemia is anticipated to boost the expansion of the asparaginase for injection market in future years. Leukemia is a form of cancer originating in blood-producing tissues, such as bone marrow, leading to an unchecked proliferation of atypical white blood cells. Globally, the incidence of leukemia is on the rise, resulting in an increasing count of new diagnoses annually. This upward trend mirrors a wider pattern in the total cancer burden, with leukemia being more frequently identified across diverse age demographics. Asparaginase for injection serves as a treatment for leukemia by reducing asparagine, an amino acid leukemia cells cannot synthesize independently, thus depriving them of sustenance and hindering their development. For example, in March 2025, a report from the US-based non-profit American Cancer Society indicates that around 22,010 individuals are predicted to be diagnosed with acute myeloid leukemia (AML) in the United States, predominantly adults. Furthermore, approximately 11,090 AML-related fatalities are forecast, primarily among adults. Consequently, the increasing prevalence of leukemia will stimulate the expansion of the asparaginase for injection market.

How Is The Pertussis Vaccine Market Classified By Different Segments?

The asparaginase for injection market covered in this report is segmented –

1) By Therapeutic Area: Oncology, Hematology, Neurology, Autoimmune Disorders

2) By Formulation Type: Lyophilized Powder, Solution For Injection, Concentrated Solution

3) By Route Of Administration: Intravenous, Intramuscular, Subcutaneous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin’s Lymphoma

Subsegments:

1) By Oncology: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Leukemia (including ALL), Lymphoma, Melanoma, Ovarian Cancer

2) By Hematology: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Anemia, Thrombocytopenia, Sickle Cell Disease

3) By Neurology: Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy, Migraine, Amyotrophic Lateral Sclerosis (ALS)

4) By Autoimmune Disorders: Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, Crohn’s Disease, Psoriasis, Type 1 Diabetes, Inflammatory Bowel Disease (IBD)

What Current And Upcoming Trends Are Shaping The Pertussis Vaccine Market?

Key companies within the asparaginase for injection market are concentrating on creating technologically advanced products, specifically recombinant medications, for treating individuals afflicted with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Recombinant medications are pharmaceutical agents produced using genetically engineered organisms to create therapeutic proteins or hormones that imitate natural human substances. For example, in July 2023, Jazz Pharmaceuticals, an Ireland-based biopharmaceutical entity, obtained approval from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for JZP458 (recombinant Erwinia asparaginase, or crisantaspase). This therapeutic option is sanctioned as part of a multi-agent chemotherapy regimen for ALL patients exhibiting hypersensitivity to E. coli-derived asparaginase, presenting an alternative for about 30% of patients who encounter difficulties with traditional treatments. Clinical investigations reveal that JZP458 effectively sustains crucial serum asparaginase activity, thereby confirming its utility in therapy.

Who Are The Primary Market Leaders In The Pertussis Vaccine Market?

Major companies operating in the asparaginase for injection market are Roche, Merck And Co, Bristol-Myers Squibb, Novartis AG, Takeda Pharmaceuticals, Amgen Inc, Intas Pharmaceuticals Ltd, Baxter International, Jazz Pharmaceuticals, Clinigen Ltd , Admac Lifesciences, Hetero Healthcare, G J Pharmaceuticals LLP, Actiza Pharmaceutical Pvt. Ltd., Taj Pharmaceuticals, Sayre Therapeutics, Aark Pharmaceuticals, Bruck Pharma Pvt Ltd, Zymeth Pharmaceuticals Pvt. Ltd., Haematologica, Aetos Pharma

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/asparaginase-for-injection-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Pertussis Vaccine Market?

North America was the largest region in the asparaginase for injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asparaginase for injection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23319&type=smp

Browse Through More Reports Similar to the Global Pertussis Vaccine Market 2025, By The Business Research Company

Fuel Injection Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fuel-injection-systems-global-market-report

Gasoline Direct Injection Gdi Device Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gasoline-direct-injection-gdi-device-global-market-report

Injection Molded Plastics Market 2025

https://www.thebusinessresearchcompany.com/report/injection-molded-plastics-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795